LEXINGTON, Mass., June 25, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today announced the appointment of Anne Prener, M.D., Ph.D., to its Board of Directors, effective July 1, 2026.
"We are delighted to welcome Dr. Prener to Keros' Board of Directors," said Jean-Jacques Bienaimé, Chair of the Board of Directors. "The combination of her clinical development expertise and executive leadership experience will be invaluable as we continue to advance our pipeline and execute on our corporate strategy. Her perspective will be instrumental in supporting the Company for long-term growth and value creation."
"I am thrilled to join Keros' Board at this exciting stage in its evolution," said Dr. Prener. "Keros has built a compelling foundation, with a differentiated scientific approach, and a clear commitment to addressing significant unmet patient needs. I look forward to working closely with the Board and executive team to support the Company's strategic priorities and continue advancing its mission of delivering meaningful and potentially disease-modifying benefits to patients."
Dr. Prener serves as a Senior Innovation Advisor at the University of Copenhagen and as non-executive director of the board of XSpray Pharma. Previously, Dr. Prener served as Chief Executive Officer of Imbria Pharmaceuticals Inc. from July 2020 until September 2024 and as venture partner at SV Health Investors from September 2020 until October 2024. From July 2017 to June 2019, Dr. Prener served as Chief Executive Officer of Freeline Therapeutics Ltd. Prior to joining Freeline, she served as Chief Executive Officer of Gyroscope Therapeutics Ltd., from August 2016 until July 2017. Before that, Dr. Prener was Global Therapeutic Area Head of Hematology and Vice President, Clinical Research Hematology at Baxalta. Earlier in her career, Dr. Prener held several positions of increasing responsibility at Novo Nordisk, most recently serving as Senior Vice President, Hemophilia R&D Portfolio. Dr. Prener previously served on the boards of directors of Galecto, Inc., Rubius Therapeutics, Inc. and Kaleido Biosciences, Inc.
Dr. Prener received a Ph.D. in epidemiology and an M.D., both from the University of Copenhagen.